Double-blind study with two butyrophenone derivatives: bromperidol vs. haloperidol.
The present report deals with a double-blind study comparing the new butyrophenone derivative, bromperidol, with haloperidol as the reference substance. Both substances were found to be highly effective in the treatment of psychotic syndromes belonging predominantly to the schizophrenia group. Certain clues, including the onset of action, seem to be indicative of the superiority of bromperidol. No differences between the two substances were observed with respect to side effects and general tolerability.
D002090:Butyrophenones / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D006220:Haloperidol / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000150:complications; D011618:Psychotic Disorders / Q000150:complications / Q000188:drug therapy*
D002090:Butyrophenones; D006220:Haloperidol